Discovery of IDO1 inhibitors: from bench to bedside
Small-molecule inhibitors of indoleamine 2, 3-dioxygenase-1 (IDO1) are emerging at the
vanguard of experimental agents in oncology. Here, pioneers of this new drug class provide …
vanguard of experimental agents in oncology. Here, pioneers of this new drug class provide …
[HTML][HTML] DNA methylation-based testing in liquid biopsies as detection and prognostic biomarkers for the four major cancer types
Lung, breast, colorectal, and prostate cancers are the most incident worldwide. Optimal
population-based cancer screening methods remain an unmet need, since cancer detection …
population-based cancer screening methods remain an unmet need, since cancer detection …
Indoleamine 2, 3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer
GC Prendergast, C Smith, S Thomas… - Cancer immunology …, 2014 - Springer
Genetic and pharmacological studies of indoleamine 2, 3-dioxygenase (IDO) have
established this tryptophan catabolic enzyme as a central driver of malignant development …
established this tryptophan catabolic enzyme as a central driver of malignant development …
[HTML][HTML] CancerLocator: non-invasive cancer diagnosis and tissue-of-origin prediction using methylation profiles of cell-free DNA
We propose a probabilistic method, CancerLocator, which exploits the diagnostic potential
of cell-free DNA by determining not only the presence but also the location of tumors …
of cell-free DNA by determining not only the presence but also the location of tumors …
Droplet-based digital PCR and next generation sequencing for monitoring circulating tumor DNA: a cancer diagnostic perspective
M Postel, A Roosen, P Laurent-Puig… - Expert review of …, 2018 - Taylor & Francis
Introduction: Early detection of cancers through the analysis of ctDNA could have a
significant impact on morbidity and mortality of cancer patients. However, using ctDNA for …
significant impact on morbidity and mortality of cancer patients. However, using ctDNA for …
Trial watch: IDO inhibitors in cancer therapy
ABSTRACT Indoleamine 2, 3-dioxygenase 1 (IDO1) catalyzes the first, rate-limiting step of
the so-called “kynurenine pathway”, which converts the essential amino acid L-tryptophan …
the so-called “kynurenine pathway”, which converts the essential amino acid L-tryptophan …
Screening for pancreatic cancer: why, how, and who?
KE Poruk, MA Firpo, DG Adler, SJ Mulvihill - Annals of surgery, 2013 - journals.lww.com
Pancreatic cancer is the fourth most common cause of cancer mortality in the United States,
with 5-year survival rates for patients with resectable tumors ranging from 15% to 20 …
with 5-year survival rates for patients with resectable tumors ranging from 15% to 20 …
[HTML][HTML] Circulating biomarkers in breast cancer
KN Seale, KHR Tkaczuk - Clinical breast cancer, 2022 - Elsevier
Breast cancer management has progressed immensely over the decades, but the disease is
still a major source of morbidity and mortality worldwide. Even with enhanced imaging …
still a major source of morbidity and mortality worldwide. Even with enhanced imaging …
[HTML][HTML] Methylation of cell-free circulating DNA in the diagnosis of cancer
K Warton, G Samimi - Frontiers in molecular biosciences, 2015 - frontiersin.org
A range of molecular alterations found in tumor cells, such as DNA mutations and DNA
methylation, is reflected in cell-free circulating DNA (circDNA) released from the tumor into …
methylation, is reflected in cell-free circulating DNA (circDNA) released from the tumor into …
Inflammatory reprogramming with IDO1 inhibitors: turning immunologically unresponsive 'cold'tumors 'hot'
We discuss how small-molecule inhibitors of the tryptophan (Trp) catabolic enzyme
indoleamine 2, 3-dioxygenase (IDO) represent a vanguard of new immunometabolic …
indoleamine 2, 3-dioxygenase (IDO) represent a vanguard of new immunometabolic …